Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4

• Published in: Journal of neuroimmunology Vol. 260; no. 1; pp. 107 - 116
• Main Authors: Miyazaki, Kaori, Abe, Yoichiro, Iwanari, Hiroko, Suzuki, Yota, Kikuchi, Takahiro, Ito, Takashi, Kato, Jungo, Kusano-Arai, Osamu, Takahashi, Toshiyuki, Nishiyama, Shuhei, Ikeshima-Kataoka, Hiroko, Tsuji, Shoji, Arimitsu, Takeshi, Kato, Yasuhiro, Sakihama, Toshiko, Toyama, Yoshiaki, Fujihara, Kazuo, Hamakubo, Takao, Yasui, Masato
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.07.2013
• Subjects: Allergy and Immunology; Amino Acid Sequence; Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Aquaporin 4 - chemistry; Aquaporin 4 - genetics; Aquaporin 4 - immunology; Aquaporin-4; Autoantibodies - chemistry; Autoantibodies - immunology; CHO Cells; Cricetinae; Flow Cytometry; Humans; Immunoglobulin G - chemistry; Immunoglobulin G - immunology; Molecular Sequence Data; Monoclonal antibody; Neurology; Neuromyelitis Optica - drug therapy; Neuromyelitis Optica - immunology; NMO-IgG; Nueromyelitis optica; Oocytes - cytology; Protein Binding - immunology; Protein Structure, Tertiary; Recombinant Proteins - chemistry; Recombinant Proteins - genetics; Recombinant Proteins - immunology; Xenopus; Nueromyelitis optica; Aquaporin-4; Monoclonal antibody; NMO-IgG
• ISSN: 0165-5728; 1872-8421
• DOI: 10.1016/j.jneuroim.2013.03.003

Abstract Neuromyelitis optica is a demyelinating disease characterized by a disease-specific autoantibody designated as NMO-IgG that specifically recognizes aquaporin-4, and the binding of NMO-IgG to AQP4 causes the progress of the disease. Prevention of the binding of NMO-IgG, therefore, may alleviate the disease. Here we have developed monoclonal antibodies against AQP4 with a baculovirus display system in order to obtain high affinity monoclonal antibodies against the extracellular domains of AQP4. Our monoclonal antibodies can block the binding of NMO-IgG in spite of their heterogeneity. Taken together, we propose that our monoclonal antibodies can be applied in clinical therapy for NMO patients.